CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Karolinska Development AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Karolinska Development AB
Tomtebodavagen 23 A
Phone: +46 852486070p:+46 852486070 SOLNA, 171 65  Sweden Ticker: KDEVKDEV
Business Summary
Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
3842 Orthopedic, prosthetic, and surgical appliances and supplies
6163 Loan brokers
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Hans L.Wigzell 86 5/16/2024 1/1/2006
Chief Executive Officer ViktorDrvota 59 6/15/2020 2/1/2016
Chief Legal Officer and Deputy Chief Executive Officer JohanDighed 51 1/1/2021 5/1/2020
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
OssDsign AB Rapsgatan 23 A UPPSALA Sweden
Sirakoss Ltd. Polwarth Building Level 4 Aberdeen Scotland United Kingdom

Business Names
Business Name
0P3C
Actar AB
Akinion Pharmaceuticals AB
11 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 12/31/2023)
Outstanding Shares: 269,833,309 (As of 6/30/2024)
Shareholders: 17,166
Stock Exchange: STO


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024